Compare Texas Instruments Incorporated (TXN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Texas Instruments Incorporated vs Vertex Pharmaceuticals Incorporated — how do they compare? Texas Instruments Incorporated trades at $293.09 (market cap $263.91B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Texas Instruments Incorporated is far larger — about 2.1× Vertex Pharmaceuticals Incorporated's market cap, and Texas Instruments Incorporated pays a 2.1% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Texas Instruments Incorporated for 76 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TXN | VRTX | |
|---|---|---|
Market Cap | $263.91B | $128.16B |
Volume | 4,544,426 | 806,603 |
Sector | Technology | Health |
52-Week High | $332.35 | $557.96 |
52-Week Low | $153.33 | $407.37 |
Typical Hold Time | 76 Days | 120 Days |
Enterprise Value | $270.96B | $122.29B |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Texas Instruments (TXN) trades at $288.2, down 3.06% today amid a semiconductor sector sell-off. The stock shows strong technical momentum with bullish moving averages and key support at $286. Fundamentally, Q2 2026 EPS beat expectations at $2.14 versus $1.91, driven by data center sales doubling. Revenue growth is accelerating with 2026 projections at $19.5B, while maintaining robust profitability with 31.11% net margins. Recent dividend payments and institutional buying by CalSTRS signal confidence.
Outlook remains positive with 47.7% analyst buy ratings and $325 consensus price target offering 13% upside. Key catalysts include AI-driven data center expansion and industrial recovery. Risks include premium valuation (P/E 43.9) and cyclical semiconductor demand. The earnings recovery trajectory supports continued growth despite near-term volatility.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
